Asset Details
Do you wish to reserve the book?
Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still’s disease/systemic lupus erythematosus: insights from nine cases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still’s disease/systemic lupus erythematosus: insights from nine cases
Do you wish to request the book?
Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still’s disease/systemic lupus erythematosus: insights from nine cases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still’s disease/systemic lupus erythematosus: insights from nine cases
2025
Overview
Macrophage activation syndrome (MAS) is frequently secondary to rheumatic diseases, with features including a cytokine storm and hemophagocytosis. Emapalumab is a monoclonal antibody that targets interferon-γ and has the ability to precisely regulate cytokines. This study aimed to investigate the efficacy and safety of low-dose emapalumab for patients with refractory MAS in the Chinese population.
From January 2022 to July 2024, 9 patients with MAS secondary to adult-onset Still's disease (AOSD) or systemic lupus erythematosus (SLE) received low-dose emapalumab following no response to prior conventional therapies. The laboratory parameters, therapeutic response, and safety were assessed following low-dose emapalumab-based treatment.
Of the nine MAS patients, 5 patients were secondary to AOSD and 4 patients were secondary to SLE. The overall response rate was 66.7% (6/9), 77.8% (7/9), 88.9% (8/9) and 88.9% (8/9) at week 1, 2, 4 and week 8, respectively. At the end of the follow-up period, up to 88.9% (8/9) of patients achieved complete remission. All patients demonstrated improvement or normalization of clinical manifestations and laboratory parameters. Notably, the median prednisone-equivalent dose for the patients was reduced by 85.5% during the treatment. Cytomegalovirus infection occurred in 33.9% (3/9) of patients, with no occurrence of serious adverse events reported.
Our findings suggest that low-dose emapalumab may be a promising salvage option for refractory MAS in the Chinese population, but confirmation in larger prospective studies is required.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Disease
/ efficacy
/ Female
/ Females
/ Fever
/ Humans
/ Lupus
/ Lupus Erythematosus, Systemic - complications
/ Lupus Erythematosus, Systemic - drug therapy
/ Macrophage Activation Syndrome - drug therapy
/ Macrophage Activation Syndrome - etiology
/ Male
/ Patients
/ refractory macrophage activation syndrome
/ safety
/ Still's Disease, Adult-Onset - complications
/ Still's Disease, Adult-Onset - drug therapy
